or Try an Advanced Search...

    Technical Analysis for NCNA - NuCana plc

    Grade Last Price % Change Price Change
    F 1.29 0.71% 0.01
    NCNA closed down 3.76 percent on Wednesday, November 20, 2024, on 4 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NCNA trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.71%
    Jack-in-the-Box Bearish Bearish Swing Setup 0.71%
    NR7 Range Contraction 0.71%
    Narrow Range Bar Range Contraction 0.71%
    Lower Bollinger Band Walk Weakness 0.71%
    Inside Day Range Contraction 0.71%
    Wide Bands Range Expansion 0.71%
    Below Lower BB Weakness 0.71%
    Down 3 Days in a Row Weakness 0.71%
    Down 4 Days in a Row Weakness 0.71%
    Older End-of-Day Signals for NCNA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Lower Bollinger Band about 3 hours ago
    Jack-in-the-Box Bearish Entry about 3 hours ago
    Fell Below Previous Day's Low about 3 hours ago
    Down 2 % about 3 hours ago
    Down 1% about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    NCNA Chart by TradingView
    Basic chart:

    Profile

    NuCana plc Description

    NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Health Sciences Treatment Of Cancer Drug Discovery Cancer Cell Solid Tumor Cancers Prodrugs Gemcitabine Organofluorides

    Is NCNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 11 NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
    Sep 25 NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
    Sep 17 NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
    Sep 16 Crude Oil Surges Over 1%; Instil Bio Shares Plunge
    Sep 16 NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
    Sep 16 NuCana soars on positive data from mid-stage trial for its melanoma treatment
    Sep 16 Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
    Sep 14 NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
    Aug 21 We're A Little Worried About NuCana's (NASDAQ:NCNA) Cash Burn Rate
    Aug 15 NuCana GAAP EPS of -£0.12
    See more NCNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 19.41
    52 Week Low 1.26
    Average Volume 1,731,987
    200-Day Moving Average 4.27
    50-Day Moving Average 2.14
    20-Day Moving Average 1.57
    10-Day Moving Average 1.48
    Average True Range 0.16
    RSI (14) 28.06
    ADX 15.12
    +DI 16.96
    -DI 31.34
    Chandelier Exit (Long, 3 ATRs) 1.43
    Chandelier Exit (Short, 3 ATRs) 1.74
    Upper Bollinger Bands 1.85
    Lower Bollinger Band 1.29
    Percent B (%b) -0.02
    BandWidth 35.67
    MACD Line -0.22
    MACD Signal Line -0.24
    MACD Histogram 0.0214
    Fundamentals Value
    Market Cap 67.58 Million
    Num Shares 52.8 Million
    EPS -0.85
    Price-to-Earnings (P/E) Ratio -1.51
    Price-to-Sales 0.00
    Price-to-Book 0.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.37
    Resistance 3 (R3) 1.38 1.36 1.36
    Resistance 2 (R2) 1.36 1.34 1.36 1.35
    Resistance 1 (R1) 1.32 1.32 1.31 1.31 1.34
    Pivot Point 1.30 1.30 1.30 1.30 1.30
    Support 1 (S1) 1.26 1.28 1.25 1.25 1.22
    Support 2 (S2) 1.24 1.26 1.24 1.21
    Support 3 (S3) 1.20 1.24 1.21
    Support 4 (S4) 1.19